Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Is Almonty Industries Poised for a Major Share Price Breakout?

Robert Sasse by Robert Sasse
November 9, 2025
in Analysis, Commodities, Earnings, Penny Stocks
0
Almonty Stock
0
SHARES
143
VIEWS
Share on FacebookShare on Twitter

A significant shift in analyst sentiment is creating a stir around Almonty Industries. The tungsten producer’s stock received a notable upgrade over the weekend, with Wall Street Zen moving its rating from “Sell” to “Hold.” This reassessment signals a potential turning point for the company, driven by dramatic quarterly performance and strategic corporate developments.

Stunning Quarterly Turnaround

The Q3 2025 financial results reveal an extraordinary corporate transformation. Almonty reported net earnings of CAD 33.2 million, a remarkable reversal from the CAD 5.3 million loss recorded during the same quarter last year. This represents an approximately CAD 40 million positive swing that has exceeded even the most optimistic market expectations.

This dramatic improvement was primarily fueled by a non-cash gain of CAD 34.5 million resulting from the revaluation of warrant liabilities. Beyond this accounting adjustment, operational performance showed solid progress, with revenues climbing 28% to CAD 8.7 million. This growth was supported by stronger tungsten pricing and consistent production output from the company’s Panasqueira mine.

Should investors sell immediately? Or is it worth buying Almonty?

Strategic Expansion Initiatives

Almonty is executing a clear three-pronged growth strategy that positions it for future expansion:

  • North American Entry: The acquisition of the Gentung Browns Lake tungsten project in Montana for USD 9.75 million marks a strategic move into the United States and strengthens North American supply chains.
  • Portuguese Development: A major drilling program is underway at the Panasqueira mine, aimed at accessing new production zones and extending the asset’s operational lifespan.
  • Korean Commissioning: The company’s flagship Sangdong mine is in the final stages before production commencement, having now entered the ramp-up phase.

Revised Market Expectations

These strong results are forcing financial analysts to recalibrate their projections. B. Riley has substantially improved its 2025 earnings forecast, now projecting a loss of just $0.08 per share compared to its previous estimate of a $0.30 per share loss.

This follows earlier positive adjustments from other firms. In October, Oppenheimer dramatically increased its price target from $7.00 to $12.00 while maintaining an “Outperform” rating. DA Davidson followed suit, raising its target to $11.00 and reaffirming its “Buy” recommendation. The emerging consensus is clear: Almonty stands to benefit significantly from rising tungsten prices and its strategic positioning as a key non-Chinese supplier of the critical metal.

Ad

Almonty Stock: Buy or Sell?! New Almonty Analysis from February 8 delivers the answer:

The latest Almonty figures speak for themselves: Urgent action needed for Almonty investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Almonty: Buy or sell? Read more here...

Tags: Almonty
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

February 8, 2026
DroneShield Stock
Analysis

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock
Analysis

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Next Post
DeFi Technologies Stock

DeFi Technologies Shares Hit 52-Week Low Amid Analyst Downgrades

Barrick Stock

Barrick's Strategic Shift Sets Stage for Crucial Earnings Report

Lynas Stock

Rare Earths Producer Lynas Defies Strong Output with Share Plunge

Recommended

Camping World Stock

Can Camping World Maintain Its Dividend Amid Market Pressures?

5 months ago
Trinity Biotech Stock

Trinity Biotech Faces Critical Nasdaq Compliance Deadline

5 months ago
DVY stock news

Amarin Strengthens Position and Maximizes Shareholder Value Through Share Repurchase Agreement with Cantor Fitzgerald

2 years ago
ASTeMobile Stock

ASTeMobile Shares Face Mounting Pressure as Investor Confidence Wanes

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Trending

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

by Jackson Burston
February 8, 2026
0

The future of Cassava Sciences appears uncertain following the definitive termination of its Alzheimer's disease program. Detailed...

DroneShield Stock

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays
  • DroneShield Shares Face Headwinds Despite Record Performance
  • Rock Tech Lithium: Investors Await the Final Go-Ahead

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com